Atherogenic dyslipidemia, metabolic syndrome and cardiovascular risk

• Published in: Cardiologia (Rome, Italy) Vol. 44; no. 10; p. 885
• Main Authors: Miccoli, R, Ceraudo, A M, Manfredi, S G, Odoguardi, L, Navalesi, R
• Format: Journal Article
• Language: Italian
• Published: Italy 01.10.1999
• Subjects: Cardiovascular Diseases - etiology; Cardiovascular Diseases - prevention & control; Coronary Artery Disease - etiology; Coronary Artery Disease - prevention & control; Humans; Hyperlipidemias - complications; Metabolic Diseases; Risk Factors; Syndrome
• ISSN: 0393-1978

The combination of high serum triglyceride levels and small low density lipoprotein particles, with a reduction in high density lipoprotein cholesterol levels has been named atherogenic lipoprotein phenotype or, simply, lipid triad. These lipid factors are commonly associated with peripheral resistance to the action of insulin, hyperinsulinism, central and visceral obesity, hypertension, hyperuricemia, hypercoagulability. The clustering of these nonlipid factors along with the lipid factors has been called metabolic syndrome. Insulin resistance plays a central role in the development of the lipid triad increasing the production of triglyceride-rich lipoproteins and decreasing their catabolism. There is currently great interest about the origins of the metabolic syndrome. One question under considerable research is whether genetic or acquired factors predominate in causing this syndrome. There seems to be little doubt that the metabolic syndrome taken as a whole constitutes a major risk factor for coronary heart disease. What is less certain is that each component of the syndrome is an independent risk factor. People with lipid triad are at very high risk of developing coronary heart disease, and careful management is warranted. Nonetheless, appropriate therapeutic strategies that will modify the metabolic syndrome as a whole are needed. More investigations about key metabolic steps that simultaneously affect multiple pathways will be required to yield a satisfactory therapy for high risk patients exhibiting the metabolic syndrome.